Search Results

There are 11709 results for: content related to: Drug development in oncology: classical cytotoxics and molecularly targeted agents

  1. Optimal Biological Dose for Molecularly Targeted Therapies

    Standard Article

    Wiley StatsRef: Statistics Reference Online

    Chul Ahn, Seung-Ho Kang, Yang Xie and Song Zhang

    Published Online : 15 FEB 2016, DOI: 10.1002/9781118445112.stat07078.pub2

  2. You have free access to this content
    New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions

    Hepatology Research

    Volume 45, Issue 10, October 2015, Pages: E1–E11, Makoto Chuma, Katsumi Terashita and Naoya Sakamoto

    Version of Record online : 9 JAN 2015, DOI: 10.1111/hepr.12459

  3. Optimal Biological Dose for Molecularly-Targeted Therapies

    Standard Article

    Wiley Encyclopedia of Clinical Trials

    Chul Ahn, Seung-Ho Kang and Yang Xie

    Published Online : 14 DEC 2007, DOI: 10.1002/9780471462422.eoct324

  4. The Price of Success: Cost-Effectiveness of Molecularly Targeted Agents

    Clinical Pharmacology & Therapeutics

    Volume 85, Issue 2, February 2009, Pages: 136–138, S Sleijfer and J Verweij

    Version of Record online : 17 DEC 2008, DOI: 10.1038/clpt.2008.245

  5. Optimal Biological Dose for Molecularly Targeted Therapies

    Methods and Applications of Statistics in Clinical Trials: Planning, Analysis, and Inferential Methods, Volume 2

    Chul Ahn, Seung-Ho Kang, Yang Xie, Pages: 496–505, 2014

    Published Online : 13 JUN 2014, DOI: 10.1002/9781118596333.ch29

  6. You have free access to this content
    Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma


    Volume 112, Issue 2, 15 January 2008, Pages: 250–259, Andrew X. Zhu

    Version of Record online : 26 NOV 2007, DOI: 10.1002/cncr.23175

  7. Anticancer drug development from traditional cytotoxic to targeted therapies: evidence of shorter drug research and development time, and shorter drug lag in Japan

    Journal of Clinical Pharmacy and Therapeutics

    Volume 37, Issue 5, October 2012, Pages: 547–552, E. Kawabata-Shoda, S. Masuda and H. Kimura

    Version of Record online : 20 MAR 2012, DOI: 10.1111/j.1365-2710.2012.01332.x

  8. You have free access to this content
    Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program


    Volume 122, Issue 8, April 15, 2016, Pages: 1228–1237, Alexander Drilon, Anne A. Eaton, Katja Schindler, Mrinal M. Gounder, David R. Spriggs, Pamela Harris, S. Percy Ivy, Alexia Iasonos, Mario E. Lacouture and David M. Hyman

    Version of Record online : 24 FEB 2016, DOI: 10.1002/cncr.29918

  9. A Bayesian dose finding design for clinical trials combining a cytotoxic agent with a molecularly targeted agent

    Journal of the Royal Statistical Society: Series C (Applied Statistics)

    Volume 64, Issue 1, January 2015, Pages: 215–229, M.-K. Riviere, Y. Yuan, F. Dubois and S. Zohar

    Version of Record online : 3 JUL 2014, DOI: 10.1111/rssc.12072

  10. You have free access to this content
    Epithelial tumours of the lacrimal gland: a clinical, histopathological, surgical and oncological survey

    Acta Ophthalmologica

    Volume 91, Issue 3, May 2013, Pages: 195–206, Sarah Linéa von Holstein, Sarah E Coupland, Daniel Briscoe, Christophe Le Tourneau and Steffen Heegaard

    Version of Record online : 4 APR 2012, DOI: 10.1111/j.1755-3768.2012.02402.x

  11. You have free access to this content
    Gemcitabine-based combinations for inoperable pancreatic cancer: Have we made real progress?


    Volume 110, Issue 3, 1 August 2007, Pages: 525–533, Emilio Bria, Michele Milella, Alain Gelibter, Federica Cuppone, Maria Simona Pino, Enzo Maria Ruggeri, Paolo Carlini, Cecilia Nisticò, Edmondo Terzoli, Francesco Cognetti and Diana Giannarelli

    Version of Record online : 18 JUN 2007, DOI: 10.1002/cncr.22809

  12. Rational Drug Design of Small Molecule Anticancer Agents: Early Clinical Development

    Standard Article

    The Cancer Handbook

    Rhoda Molife, Ian Collins, Paul Workman and Stan B. Kaye

    Published Online : 15 OCT 2007, DOI: 10.1002/9780470025079.chap315

  13. Heart Failure Caused by Molecularly Targeted Therapies for Cancer

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 31, Issue 1, January 2011, Pages: 62–75, Dr. Anthony Jarkowski III, Ashley E. Glode, Dr. Edward J. Spangenthal and Dr. Michael K. K. Wong

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.31.1.62

  14. You have full text access to this Open Access content
    Molecularly targeted therapy for hepatocellular carcinoma

    Cancer Science

    Volume 100, Issue 1, January 2009, Pages: 1–8, Shinji Tanaka and Shigeki Arii

    Version of Record online : 25 NOV 2008, DOI: 10.1111/j.1349-7006.2008.01006.x

  15. You have full text access to this OnlineOpen article
    Comprehensive transcriptomic analysis of molecularly targeted drugs in cancer for target pathway evaluation

    Cancer Science

    Volume 106, Issue 7, July 2015, Pages: 909–920, Tetsuo Mashima, Masaru Ushijima, Masaaki Matsuura, Satomi Tsukahara, Kazuhiro Kunimasa, Aki Furuno, Sakae Saito, Masami Kitamura, Taeko Soma-Nagae, Hiroyuki Seimiya, Shingo Dan, Takao Yamori and Akihiro Tomida

    Version of Record online : 25 MAY 2015, DOI: 10.1111/cas.12682

  16. A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials

    Pediatric Blood & Cancer

    Volume 64, Issue 3, March 2017, Kathleen Dorris, Chunyan Liu, Dandan Li, Trent R. Hummel, Xia Wang, John Perentesis, Mi-Ok Kim and Maryam Fouladi

    Version of Record online : 22 SEP 2016, DOI: 10.1002/pbc.26258

  17. Dose escalation trial designs based on a molecularly targeted endpoint

    Statistics in Medicine

    Volume 24, Issue 14, 30 July 2005, Pages: 2171–2181, Sally Hunsberger, Lawrence V. Rubinstein, Janet Dancey and Edward L. Korn

    Version of Record online : 20 MAY 2005, DOI: 10.1002/sim.2102

  18. You have free access to this content
    Development of molecularly targeted therapies in biliary tract cancers: Reassessing the challenges and opportunities


    Volume 53, Issue 2, February 2011, Pages: 695–704, Andrew X. Zhu and Aram F. Hezel

    Version of Record online : 27 JAN 2011, DOI: 10.1002/hep.24145

  19. You have full text access to this OnlineOpen article
    Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering

    Statistics in Medicine

    Volume 34, Issue 5, 28 February 2015, Pages: 859–875, Beibei Guo and Yisheng Li

    Version of Record online : 21 NOV 2014, DOI: 10.1002/sim.6376

  20. Clinical Development Issues

    Molecular Cancer Therapeutics: Strategies for Drug Discovery and Development

    Steven D. Averbuch, Michael K. Wolf, Basil F. El-Rayes, Patricia M. LoRusso, Pages: 287–306, 2005

    Published Online : 28 JAN 2005, DOI: 10.1002/047165616X.ch13